Scientists at the University of Leicester in the United Kingdom recently published phase 2 clinical trial results involving abemaciclib, a new genetic therapy for…
The National Cancer Institute has opened a promising clinical trial aimed at increasing the effectiveness of immunotherapy treatment for patients with unresectable malignant…
Researchers have made significant progress in mesothelioma treatment advancements recently, including promising work with immunotherapy. The first U.S. Food and Drug Administration-approved combination…
When the effectiveness of first-line chemotherapy fails and malignant mesothelioma returns, more patients could soon turn with confidence to a proven, second-line…
A recently amended California law will now allow the estates of deceased plaintiffs, including mesothelioma patients, to collect pain and suffering damages.
As expected, Johnson & Johnson has unloaded its burgeoning talc-related liabilities on a new subsidiary that filed for Chapter 11 bankruptcy protection on…
Your web browser is no longer supported by Microsoft. Update your browser for more security, speed and compatibility.
If you are looking for mesothelioma support, please contact our Patient Advocates at (855) 404-4592
Who Am I Calling?
Calling this number connects you with a Patient Advocate at The Mesothelioma Center, the nation's most trusted mesothelioma resource.
Our Patient Advocates can help guide you or your loved one through the steps to take after a mesothelioma diagnosis. Our team has a combined experience of more than 30 years in assisting cancer patients, and includes a medical doctor, an oncology registered nurse and a U.S. Navy veteran.
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Please read our editorial guidelines to learn more about our content creation and review process.
